|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||24.02 / 68.05|
Investors in Global Blood Therapeutics Inc saw new options begin trading this week, for the August 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GBT options chain for the new August 17th contracts and identified one put and one call contract of particular interest.
You don't have to 'believe' in technical analysis to use it to set your exit and entry points.
There is no question that we are becoming extended and ripe for some profit taking.
Overall it is still a positive day but the action is sloppy.
No matter what happens with Iran, it is not going to be a major market positive.
Investors in Global Blood Therapeutics Inc saw new options become available today, for the July 20th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 87 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
These names are showing technical characteristics of either bullish or bearish reversal patterns over the past week.
Appointment Strengthens Management Team as Company Advances Clinical Development of Voxelotor, a Potential Disease-Modifying Therapy for Sickle Cell Disease
It is important to note that watching for a reversal is much different than being short.
The bears are likely to be increasingly bold if there's a failed bounce.
It would be a longer-term positive if the overbought conditions are alleviated.
You have to wonder how much longer we can run without a pullback of at least 2%.
There is still a very strong appetite for individual stocks with momentum.
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Global Blood Therapeutics Inc , where a total volume of 6,399 contracts has been traded thus far today, a contract volume which is representative of approximately 639,900 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 43.1% of GBT's average daily trading volume over the past month, of 1.5 million shares.
Voxelotor is First Investigational Treatment for SCD to Receive Breakthrough Therapy Designation
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.